References
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 (Suppl. 7):1–96
- Kaube H, Hoskin K, Goadsby P. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in dorsal horn of the upper cervical spinal cord in the cat. Headache, 1993; 33: 541–4
- Talley JJ. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Medic Chem 1999;36:201–34
- Tfelt-Hansen P. Prophylactic treatment of migraine; evaluation of clinical trials and choice among drugs. Cephalalgia 1995;15:29–32
- Pharmacology and use of headache medication. Cleveland Clin J Med 1990;57:627–35
- Johnson ES, Ratcliff DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985;5:5–10
- Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985;5: 107–12
- Kloster R, Nestvold K, Seinar T, et al. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12:169–71
- Sandrini G, Franchini S, Lanfranchi S, et al. Effectiveness of ibuprofen–argenine in the treatment of acute migraine attacks. Int J Clin Pharm Res 1998;XVIII:145–50
- Hakkarainen H, Vapaatalo H. Tolfenamic acid is as effective as egotamine during migraine attacks. Lancet 1979;18: 326–8
- Rasmussen MJK, Hansen AW, Schmidt-Hansen PT, et al. A placebo-controlled trial with tolfenamic acid 200 mg and sumatriptan 100 mg in acute treatment of migraine. Oral presentation at the 9th Congress of the International Headache Society in Barcelona, 1999
- Myllylä VV, Havanka H, Herrela L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38: 201–7
- Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999;19:186–7
- McNeely W, Goa KL. Diclofenac–potassium in migraine. A review. Drugs 1999;57:991–1003
- Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990;30:710–15
- Rasmussen MJK, Larsen BH, Borg L, et al. Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. Acta Neurol Scand 1994; 89:446–50
- Al-Waili NSD. Treatment of menstrual migraine with pros-taglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res 2000;5:176–82
- Solomon GD. Therapeutic advances in migraine. J Clin Pharmacol 1993;33:200–9
- Diener HC, Kaube H, Limmroth V. A practical guide to management and prevention of migraine. Drugs 1998;56: 811–24
- Peterson WL, Cryer B. COX-1 sparing NSAIDs – is the enthusiasm justified? JAMA 1999;282:1961–3
- Malmstrom K, Daniels S, Kotey P, et al. Comparison of refecoxib and celecoxib, two COX-2 inhibitors in postoperative dental pain: a randomized, placebo- and active comparator controlled clinical trial. Clin Ther 1999;21: 1653–63